Over the past 12 months, 7 insiders at IRONWOOD PHARMACEUTICALS INC filed 21 open-market SEC Form 4 transactions on IRWD: 0 purchases worth $0 and 21 sales worth $22.6M. Insiders have been net sellers over this period. The most recent filing was on Jul 7, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 7, 26 | Ronald SilverPFO & PAO | SELL | 127.9K | $4.52 | $578K |
| Mar 17, 26 | Alexander J DennerDirector | SELL | 6.72M | $3.31 | $20.5M |
| Feb 24, 26 | Tammi L GaskinsChief Commercial Officer | SELL | 11.2K | $3.66 | $41K |
| Feb 24, 26 | Minardo JohnChief Legal Officer | SELL | 19.1K | $3.66 | $70K |
| Feb 24, 26 | Thomas A McCourtChief Executive Officer | SELL | 103.5K | $3.66 | $379K |
| Feb 24, 26 | Gregory S. MartiniChief Financial Officer | SELL | 11.5K | $3.66 | $42K |
| Feb 24, 26 | Michael ShetzlineSVP, CMO, Head-Res&Drug | SELL | 17.0K | $3.66 | $62K |
| Feb 24, 26 | Ronald SilverPrincipal Accounting Officer | SELL | 12.6K | $3.66 | $46K |
| Feb 23, 26 | Tammi L GaskinsChief Commercial Officer | SELL | 10.3K | $3.81 | $39K |
| Feb 23, 26 | Minardo JohnChief Legal Officer | SELL | 17.4K | $3.81 | $66K |
| Feb 23, 26 | Thomas A McCourtChief Executive Officer | SELL | 94.8K | $3.81 | $361K |
| Feb 23, 26 | Gregory S. MartiniChief Financial Officer | SELL | 10.5K | $3.81 | $40K |
| Feb 23, 26 | Michael ShetzlineSVP, CMO, Head-Res&Drug | SELL | 15.6K | $3.81 | $59K |
| Feb 23, 26 | Ronald SilverPrincipal Accounting Officer | SELL | 11.6K | $3.81 | $44K |
| Jan 5, 26 | Ronald SilverPrincipal Accounting Officer | SELL | 35.4K | $4.60 | $163K |
| Nov 17, 25 | Tammi L GaskinsChief Commercial Officer | SELL | 6.0K | $3.32 | $20K |
| Aug 11, 25 | Tammi L GaskinsChief Commercial Officer | SELL | 1.3K | $0.84 | $1K |
| Aug 11, 25 | Minardo JohnChief Legal Officer | SELL | 7.8K | $0.84 | $7K |
| Aug 11, 25 | Gregory S. MartiniChief Financial Officer | SELL | 1.3K | $0.84 | $1K |
| Aug 11, 25 | Ronald SilverPrincipal Accounting Officer | SELL | 2.8K | $0.84 | $2K |
| May 16, 25 | Tammi L GaskinsChief Commercial Officer | SELL | 2.6K | $0.58 | $1K |
| May 16, 25 | Thomas A McCourtChief Executive Officer | SELL | 13.4K | $0.58 | $8K |
| Feb 10, 25 | Minardo JohnChief Legal Officer | SELL | 38.9K | $1.76 | $69K |
| Feb 10, 25 | Thomas A McCourtChief Executive Officer | SELL | 139.1K | $1.76 | $245K |
| Feb 10, 25 | Gregory S. MartiniChief Financial Officer | SELL | 12.1K | $1.76 | $21K |
| Feb 10, 25 | Michael ShetzlineSVP, CMO, Head-Res&Drug | SELL | 41.3K | $1.76 | $73K |
| Feb 10, 25 | Ronald SilverPrincipal Accounting Officer | SELL | 12.0K | $1.76 | $21K |
| Nov 18, 24 | Andrew DavisSVP, Chief Business Officer | SELL | 5.4K | $4.08 | $22K |
| Nov 18, 24 | Sravan Kumar EmanySVP, COO and CFO | SELL | 11.0K | $4.08 | $45K |
| Aug 12, 24 | Minardo JohnChief Legal Officer | SELL | 9.9K | $4.27 | $42K |
| Aug 12, 24 | Ronald SilverPrincipal Accounting Officer | SELL | 3.1K | $4.27 | $13K |
| Jun 10, 24 | Julie McHughDirector | SELL | 22.8K | $6.29 | $143K |
| Jun 7, 24 | Catherine MoukheibirDirector | SELL | 35.6K | $6.61 | $235K |
| Jun 6, 24 | Catherine MoukheibirDirector | SELL | 44.4K | $6.36 | $283K |
| May 20, 24 | Andrew DavisSVP, Chief Business Officer | SELL | 22.7K | $6.45 | $147K |
| May 20, 24 | Minardo JohnChief Legal Officer | SELL | 17.4K | $6.45 | $112K |
| May 20, 24 | Thomas A McCourtChief Executive Officer | SELL | 67.6K | $6.45 | $436K |
| May 20, 24 | Michael ShetzlineCMO,SVP,Head-Res&Drug | SELL | 16.1K | $6.45 | $104K |
| Mar 6, 24 | Jon R DuaneDirector | BUY | 6.9K | $8.70 | $60K |
| Mar 4, 24 | Sravan Kumar EmanySVP, Chief Financial Officer | BUY | 10.7K | $9.38 | $100K |
| Feb 12, 24 | Andrew DavisSVP, Chief Business Officer | SELL | 9.8K | $15.24 | $150K |
| Feb 12, 24 | Minardo JohnChief Legal Officer | SELL | 47.4K | $15.24 | $722K |
| Feb 12, 24 | Thomas A McCourtChief Executive Officer | SELL | 177.2K | $15.24 | $2.7M |
| Feb 12, 24 | Michael ShetzlineCMO,SVP,Head-Res&Drug | SELL | 38.6K | $15.24 | $589K |
| Feb 12, 24 | Ronald SilverPrincipal Accounting Officer | SELL | 7.9K | $15.24 | $121K |
| Dec 14, 23 | Marla L KesslerDirector | SELL | 9.9K | $11.19 | $111K |
| Nov 20, 23 | Andrew DavisSVP, Chief Business Officer | SELL | 3.3K | $9.69 | $32K |
| Sep 15, 23 | Sravan Kumar EmanySVP, Chief Financial Officer | BUY | 36.1K | $8.32 | $300K |
| Aug 14, 23 | Minardo JohnChief Legal Officer | SELL | 7.0K | $10.04 | $71K |
| Aug 14, 23 | Ronald SilverPrincipal Accounting Officer | SELL | 2.0K | $10.04 | $20K |
Over the past 12 months, insiders at IRONWOOD PHARMACEUTICALS INC filed 0 open-market purchases worth $0 and 21 sales worth $22.6M on IRWD, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 7, 26.
The largest recent open-market IRWD insider purchase in our data was $300K by Sravan Kumar Emany, SVP, Chief Financial Officer, filed on Sep 15, 23.
7 different insiders at IRONWOOD PHARMACEUTICALS INC filed open-market SEC Form 4 transactions on IRWD over the last 12 months.
InsiderTape plots every IRWD insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every IRONWOOD PHARMACEUTICALS INC insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →